MedPath

NMPA Approvals

Chinese National Medical Products Administration approved drug approval numbers and registration information

National Medical Products Administration
China
166,322 Approvals
Showing 1421 to 1440 of 166,322 approvalsPage 72 of 8317

Fenofibrate Tablets (III)

Approval Number: 国药准字H20253424
Registration: Feb 20, 2025

Proparacaine Hydrochloride Eye Drops

Approval Number: 国药准字H20253428
Registration: Feb 20, 2025

Famotidine Injection

Approval Number: 国药准字H20253432
Registration: Feb 20, 2025

Phloroglucinol Injection

Approval Number: 国药准字H20253419
Registration: Feb 20, 2025

Levofloxacin and Sodium Chloride Injection

Approval Number: 国药准字H20253438
Registration: Feb 20, 2025

Esomeprazole Magnesium Enteric-coated Capsules

Approval Number: 国药准字H20253396
Registration: Feb 20, 2025

Pranoprofen Eye Drops

Approval Number: 国药准字H20253411
Registration: Feb 20, 2025

Ambroxol Hydrochloride Oral Solution

Approval Number: 国药准字H20253390
Registration: Feb 20, 2025

Compound Amino Acids Injection(18AA-Ⅶ)

Approval Number: 国药准字H20253421
Registration: Feb 20, 2025

Ambroxol Hydrochloride and Clenbuterol Hydrochloride Oral Solution

Approval Number: 国药准字H20253382
Registration: Feb 20, 2025

Tenapanor Hydrochloride Tablets

Approval Number: 国药准字HJ20250021
Registration: Feb 20, 2025

Acipimox Capsules

Approval Number: 国药准字H20253441
Registration: Feb 20, 2025

Compound Sodium Acetate Ringer’s Injection

Approval Number: 国药准字H20253389
Registration: Feb 20, 2025

Tranexamic Acid Tablets

Approval Number: 国药准字H20253413
Registration: Feb 20, 2025

Phloroglucinol Injection

Approval Number: 国药准字H20253420
Registration: Feb 20, 2025

Bupivacaine Hydrochloride Injection

Approval Number: 国药准字H20258019
Registration: Feb 19, 2025

小儿退热口服液

Approval Number: 国药准字Z37020945
Registration: Feb 19, 2025

Sodium Bicarbonate Injection

Approval Number: 国药准字H20258017
Registration: Feb 19, 2025

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Product

Company

Legal

© 2025 MedPath, Inc. All rights reserved.